Preview

Рецепт

Расширенный поиск

Обновленные европейские рекомендации по ведению пациентов с волчаночным нефритом

https://doi.org/10.34883/PI.2020.2.2.049

Полный текст:

Аннотация

Системная красная волчанка – это хроническое аутоиммунное ревматическое заболевание, в основе патогенеза которого лежат дефекты иммунорегуляции, приводящие к неконтролируемой гиперпродукции аутоантител к компонентам собственных тканей и развитию хронического воспаления, затрагивающего многие органы и системы. Почки чаще других вовлекаются в патологический процесс. Одним из наиболее тяжелых проявлений является развитие волчаночного нефрита. Несмотря на успехи в изучении патогенеза и разработанных современных схем лечения этого серьезного осложнения, сохраняется высокий риск развития у этих пациентов терминальной стадии хронической почечной недостаточности с необходимостью применения методов заместительной почечной терапии (диализ и трансплантация почки), а также повышения сердечно-сосудистых катастроф и прочих коморбидных состояний, сокращающих продолжительность жизни. За прошедшие годы появились новые данные, касающиеся ранней диагностики, мониторирования течения и лечения волчаночного нефрита, в связи с чем возникла необходимость внесения ряда дополнений и изменений в прежние рекомендации по ведению волчаночного нефрита с учетом накопленного мирового опыта. В данном обзоре приведена краткая информация об основных положениях новых рекомендаций EULAR/ERA-EDTA, опубликованных в 2019 г.

Об авторах

К. А. Чиж
Белорусский государственный медицинский университет
Беларусь


А. К. Тушина
Белорусский государственный медицинский университет
Беларусь


Список литературы

1. Hanly J.G., O’Keeffe A.G., Su L. et al. (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, vol. 55, no 2, pp. 252–262.

2. Bertsias G.K., Tektonidou M., Amoura Z. et al. (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis, vol. 71, no 11, pp. 1771–1782.

3. Tektonidou M.G., Dasgupta A., Ward M.M. (2016) Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol, vol. 68, no 6, pp. 1432–1441.

4. Moroni G., Vercelloni P.G., Quaglini S. et al. (2018) Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis, vol. 77, no 9, pp. 1318-1325.

5. Weening J.J., D’Agati V.D., Schwartz M.M. et al. (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int, vol. 65, no 2, pp. 521–530.

6. Mejia-Vilet J.M., Cordova-Sanchez B.M., Uribe-Uribe N.O. et al. (2017) Prognostic significance of renal vascular pathology in lupus nephritis. Lupus, vol. 26, no 10, pp. 1042–1050.

7. Bajema I.M., Wilhelmus S., Alpers C.E. et al. (2018) Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int, vol. 93, no 4, pp. 789–796.

8. Dall’Era M., Cisternas M.G., Smilek D.E. et al. (2015) Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro- Lupus nephritis cohort. Arthritis Rheumatol, vol. 67, no 5, pp. 1305–1313.

9. Fanouriakis A., Kostopoulou M., Alunno A. et al. (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis, vol. 78, no 6, pp. 736–745.

10. Tunnicliffe D.J., Palmer S.C., Henderson L. et al. (2018) Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev, no 6:CD002922.

11. Mehra S., Usdadiya J.B., Jain V.K. et al. (2018) Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatol Int, vol. 38, no 4, pp. 557–568.

12. Boumpas D.T., Austin H.A., Vaughn E.M. et al. (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet, vol.340, no 8822, pp. 741–745.

13. Ruiz-Irastorza G., Danza A., Perales I. et al. (2014) Prednisone in lupus nephritis: how much is enough? Autoimmun Rev, vol. 13, no 2, pp. 206–214.

14. Rovin B.H., Solomons N., Pendergraft W.F. et al. (2019) A randomized, controlled double-blind study comparing the efficacy and safety of dose- ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int, vol. 95, no 1, pp. 219–231.

15. Palmer S.C., Tunnicliffe D.J., Singh-Grewal D. et al. (2017) Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis, vol. 70, no 3, pp. 324–336.

16. Yap D.Y.H., Yu X., Chen X.-M. et al. (2012) Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology, vol. 17, no 4, pp. 352–357.

17. Fervenza F.C., Appel G.B., Barbour S.J. et al. (2019) Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med, vol. 381, no 1, pp. 36–46.

18. Mok C.C., Tse S.M., Chan K.L. et al. (2018) Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus, vol. 27, no 5, pp. 722–727.

19. Marmor M.F., Kellner U., Lai T.Y.Y. et al. (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology, vol. 123, no 6, pp. 1386–1394.

20. Yap D.Y.H., Tang C., Ma M.K.M. et al. (2017) Longterm data on disease flares in patients with proliferative lupus nephritis in recent years. J Rheumatol, vol. 44, no 9, pp. 1375–-1383.

21. Moroni G., Gatto M., Raffiotta F. et al. (2018) Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmun Rev, vol.17, no 1, pp. 11–18.

22. Kasitanon N., Boripatkosol P., Louthrenoo W. (2018) Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis, vol. 21, no 1, pp. 200–207.

23. Alshaiki F., Obaid E., Almuallim A. et al. (2018) Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol, vol. 5, no 2, pp. 118–126.

24. McCarthy E.M., Sutton E., Nesbit S. et al. (2018) Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles lupus assessment group biologics register. Rheumatology, vol. 57, no 3, pp. 470–479.

25. Sciascia S., Radin M., Yazdany J. et al. (2017) Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev, vol. 16, no 3, pp. 287–293.

26. Sakthiswary R., D’Cruz D. (2014) Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis. Medicine, vol. 93, no 16:e86.

27. Tselios K., Koumaras C., Urowitz M.B. et al. (2014) Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. Semin Arthritis Rheum, vol. 43, no 4, pp. 521–525.

28. van Assen S., Agmon-Levin N., Elkayam O. et al. (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis, vol. 70, no 3, pp. 414–422.

29. Piepoli M.F., Hoes A.W., Agewall S. et al. (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J, vol. 37, no 29, pp. 2315–2381.

30. Tektonidou M.G., Andreoli L., Limper M. et al. (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis, vol. 78, no 10, pp. 1296–1304.

31. Arora S., Nika A., Trupin L. et al. (2018) Does systemic lupus erythematosus care provided in a lupus clinic result in higher quality of care than that provided in a general rheumatology clinic? Arthritis Care Res, vol. 70, no 12, pp. 1771–1777.

32. Medina-Rosas J., Yap K.S., Anderson M. et al. (2016) Utility of urinary Protein-Creatinine ratio and protein content in a 24-hour urine collection in systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res, vol. 68, no 9, pp. 1310–1319.

33. Narváez J., Ricse M., Gomà M. et al. (2017) The value of repeat biopsy in lupus nephritis flares. Medicine, vol. 96, no 24:e7099.

34. Hajji M., Harzallah A., Kaaroud H. et al. (2017) Factors associated with relapse of lupus nephritis: a single center study of 249 cases. Saudi J Kidney Dis Transpl, vol. 28, no 6, pp. 1349–1355.

35. Bock M., Heijnen I., Trendelenburg M. (2015) Anti-C1q antibodies as a follow-up marker in SLE patients. PLoS One, vol. 10, no 4:e0123572.

36. Malvar A., Pirruccio P., Alberton V. et al. (2017) Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant, vol. 32, no 8, pp. 1338–1344.

37. De Rosa M., Azzato F., Toblli J.E. et al. (2018) A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int, vol. 94, no 4, pp. 788–794.

38. Jorge A., Wallace Z.S., Zhang Y. et al. (2019) All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol, vol. 71, no 3, pp. 403–410.

39. Levy B., Couchoud C., Rougier J.-P. et al. (2015) Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French national registry 2002-2012. Lupus, vol. 24, no 10, pp. 1111–1121.

40. Jorge A., Wallace Z.S., Lu N. et al. (2019) Renal transplantation and survival among patients with lupus nephritis: a cohort study. Ann Intern Med, vol. 170, no 4, pp. 240-247.

41. Park M.H., Caselman N., Ulmer S. et al. (2018) Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv, vol. 2, no 16, pp. 2090–2094.

42. Yue C., Li G., Wen Y. et al. (2018) Early renin-angiotensin system blockade improved shortterm and longterm renal outcomes in systemic lupus erythematosus patients with antiphospholipid-associated nephropathy. J Rheumatol, vol. 45, no 5, pp. 655–662.

43. Andreoli L., Bertsias G.K., Agmon-Levin N. et al. (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis, vol. 76, pp. 476–485.

44. Fischer-Betz R., Specker C., Brinks R. et al. (2013) Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology, vol. 52, no 6, pp. 1070–1076.

45. Groot N., de Graeff N., Marks S.D. et al. (2017) European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis, vol. 76, no 12, pp. 1965–1973.

46. Aringer M., Costenbader K., Daikh D. et al. (2019) 2019 European League against Rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis, vol. 78, no 9, pp. 1151–1159.

47. Fanouriakis A., Kostopoulou M., Alunno A. et al. (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis, vol. 78, no 6, pp. 736–745.


Для цитирования:


Чиж К.А., Тушина А.К. Обновленные европейские рекомендации по ведению пациентов с волчаночным нефритом. Рецепт. 2020;(2-3):430-442. https://doi.org/10.34883/PI.2020.2.2.049

For citation:


Chyzh .K., Tushina .A. Updated European Guidelines for the Management of Lupus Nephritis Patients. Recipe. 2020;(2-3):430-442. (In Russ.) https://doi.org/10.34883/PI.2020.2.2.049

Просмотров: 15


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)